#1108

A 10-year single center experience review of partial cystectomy from 2014 to 2024

T. Li¹, C. Chang¹, C. Huang¹, C. Yeh¹, C. Yang¹

¹China Medical University Hospital, Urology, Taichung, Taiwan

Introduction:

Partial cystectomy (PC) is a bladder-sparing treatment option for bladder cancer, intended for a carefully selected group of patients. Neoadjuvant therapy has gained popularity in recent years, and immunotherapy as a neoadjuvant treatment has shown promising results in cancer control. This study aimed to evaluate the outcomes of PC in a recent cohort of patients treated at a single institution.

Material and methods:

Medical records were reviewed for 39 patients diagnosed with primary urothelial carcinoma (UC) who underwent partial cystectomy with curative intent at China Medical University Hospital between 2013 and 2024. The primary endpoints included noninvasive recurrence (defined as any recurrence of non-muscle invasive disease), advanced recurrence (defined as muscle-invasive recurrence or metastasis), and mortality. Unadjusted Cox proportional hazards regression and log-rank tests were employed to assess associations between clinical characteristics and these endpoints.

Results:

In a cohort of 39 patients with bladder cancer treated by partial cystectomy, the median age was 75.8 years (interquartile range 45-91), with 69% male patients. Preoperative neoadjuvant chemotherapy (NAC) was administered to 54% of patients. Pathologic staging revealed that 62% had tumors classified as